Armistice Capital’s Traws Pharma TRAW Stock Holding History

Armistice Capital’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-78	Closed	-$62K	–	89
2018 Q4	$62K	Sell	78 -219	-74%	-$373K	﹤0.01%	70
2018 Q3	$816K	Sell	297 -3	-1%	-$7.65K	0.05%	72
2018 Q2	$683K	Buy	300 +60	+25%	+$174K	0.04%	69
2018 Q1	$1.13M	Buy	+240	New	+$1.71M	0.09%	60

Other funds holding TRAW

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's TRAW Position: Q1 2019 in Review

Armistice Capital sold out of Traws Pharma (TRAW) in Q1 2019, closing a stake of 78 shares — an estimated $62K sold.

Armistice Capital first reported a position in TRAW in Q1 2018 and held it in 4 quarters. The position peaked at $1.13M in Q1 2018. 12 funds tracked by Wall St. Rank hold TRAW as of Q1 2019.

Armistice Capital reported no remaining Traws Pharma position as of Q1 2019 after selling out during the quarter.
Armistice Capital sold 78 Traws Pharma shares in Q1 2019, an estimated $62K.
Armistice Capital first reported a position in Traws Pharma in Q1 2018 and held it in 4 quarters.
Armistice Capital's Traws Pharma position peaked at $1.13M in Q1 2018.
12 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2019.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.